<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606134</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003126</org_study_id>
    <nct_id>NCT04606134</nct_id>
  </id_info>
  <brief_title>Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring</brief_title>
  <official_title>A Single Center, Prospective, Blinded Study to Evaluate the Efficacy and Safety of a Tripeptide/Hexapeptide Topical When Used With Er:YAG Hybrid Laser for the Treatment of Acne Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin&#xD;
      Nectar with TriHex TechnologyÂ®) in wound healing and scar reduction following Erbium:YAG&#xD;
      hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care&#xD;
      consisting of a bland moisturizer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in erythema</measure>
    <time_frame>baseline to day 34</time_frame>
    <description>A colorimeter will be used to measure the erythema index. The range of the index is 0 to X with 0 indicating better outcome. Erythema will be measured at days of laser treatment and 4 days after treatment. Laser treatment will occur at baseline and day 30. The mean change for each laser treatment will be averaged to get the overall mean for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in skin barrier function</measure>
    <time_frame>baseline to day 34</time_frame>
    <description>Barrier function will be measured by transepidermal water loss in grams/m2(hour). The lower the water loss the better the barrier function of the skin. Barrier function will be measured at days of laser treatment and 4 days after treatment. Laser treatment will occur at baseline and day 30. The mean change for each laser treatment will be averaged to get the overall mean for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Global Aesthetic Improvement Scale</measure>
    <time_frame>baseline to day 90</time_frame>
    <description>The Global Aesthetic Improvement Scale ranges from 1 to 5 with lower numbers indicating better outcomes. (1 = very much improved,2 = marked improvement, 3 = improved, 4 = no change, 5 = worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acne Scars - Mixed Atrophic and Hypertrophic</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid fractional laser</intervention_name>
    <description>two treatments given one month apart</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alastin Regenerating Skin Nectar with TriHex Technology</intervention_name>
    <description>applied twice daily</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil face cream</intervention_name>
    <description>applied twice daily</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or females&#xD;
&#xD;
          -  age 18 and older&#xD;
&#xD;
          -  with evidence of grade II-III acne scars on the face (mild to moderate) as determined&#xD;
             by the Goodman &amp; Baron qualitative global acne scar grading system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  treatment to face with any energy device within 6 months&#xD;
&#xD;
          -  tanning within 7 days&#xD;
&#xD;
          -  dermabrasion or chemical peel within 3 months&#xD;
&#xD;
          -  current use of systemic retinoids&#xD;
&#xD;
          -  keloidal scaring in the treatment area&#xD;
&#xD;
          -  use of systemic steroids within 6 months&#xD;
&#xD;
          -  use of topical products with retinoid, alpha-hydroxyacid, salicylic acid, vitamin C or&#xD;
             E within 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Mara Weinstein Velez, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

